Editor-in-Chief; Eskişehir-Turkey.

The ACC 2017 meeting was held in Washington D.C. between March 17 and 19, 2017. Although the meeting had an overall scientific impact, it was partly affected by the travel bans of colleagues from some countries. Herein, we discuss some highlights of the meeting. The most striking aspect of ACC 2017 was the presentation of plenty of late-breaking clinical trials. The most striking among all was “FOURIER” trial in which Turkish scientists had also participated (1). Evolocumab therapy resulted in 59% further reduction of LDL cholesterol compared to standard care. The FOURIER trial shows that evolocumab, which is a fully human monoclonal antibody against PCSK9, causes a significant reduction of 15% in the primary end-points of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; in addition, it also causes a significant reduction of 20% in some secondary end-points of cardiovascular death, myocardial infarction, or stroke. Notably, the benefit was driven by reductions in the incidence of nonfatal AMI, stroke, and coronary revascularization, but the incidence of cardiovascular (CV) death remained similar in both groups. However, it is important to note that cost issues were of concern even in the USA.